AU2017271550B2 - Method of treating cancer by targeting myeloid-derived suppressor cells - Google Patents

Method of treating cancer by targeting myeloid-derived suppressor cells Download PDF

Info

Publication number
AU2017271550B2
AU2017271550B2 AU2017271550A AU2017271550A AU2017271550B2 AU 2017271550 B2 AU2017271550 B2 AU 2017271550B2 AU 2017271550 A AU2017271550 A AU 2017271550A AU 2017271550 A AU2017271550 A AU 2017271550A AU 2017271550 B2 AU2017271550 B2 AU 2017271550B2
Authority
AU
Australia
Prior art keywords
cancer
drug
folate receptor
myeloid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017271550A
Other languages
English (en)
Other versions
AU2017271550A1 (en
Inventor
Christopher Paul Leamon
Philip Stewart Low
Yingjuan J. LU
Bingbing Wang
Leroy W. WHEELER II
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Endocyte Inc
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Publication of AU2017271550A1 publication Critical patent/AU2017271550A1/en
Application granted granted Critical
Publication of AU2017271550B2 publication Critical patent/AU2017271550B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AU2017271550A 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells Active AU2017271550B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
US62/341,587 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Publications (2)

Publication Number Publication Date
AU2017271550A1 AU2017271550A1 (en) 2018-12-06
AU2017271550B2 true AU2017271550B2 (en) 2023-11-02

Family

ID=60412652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017271550A Active AU2017271550B2 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Country Status (8)

Country Link
US (2) US20190216935A1 (cg-RX-API-DMAC7.html)
EP (1) EP3463367A4 (cg-RX-API-DMAC7.html)
JP (1) JP7278777B2 (cg-RX-API-DMAC7.html)
KR (1) KR102489277B1 (cg-RX-API-DMAC7.html)
CN (2) CN109475558A (cg-RX-API-DMAC7.html)
AU (1) AU2017271550B2 (cg-RX-API-DMAC7.html)
IL (1) IL263059B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017205661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019317278B2 (en) * 2018-08-07 2025-05-22 Purdue Research Foundation Rejuvenation of CAR T cell
CN114269346A (zh) * 2019-07-08 2022-04-01 普渡研究基金会 用于治疗和预防纤维化疾病状态和癌症的化合物和方法
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
EP4271378A4 (en) * 2021-01-04 2026-03-11 Purdue Research Foundation METHODS FOR IMPROVING MODIFIED CELL THERAPIES IN CANCER TREATMENT
CN118829726A (zh) 2022-03-08 2024-10-22 科纳斯特股份有限公司 包含胶原酶、钙、组氨酸及甘氨酸的组合物及胶原酶的稳定化方法
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062697A2 (en) * 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016085967A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2470668C2 (ru) 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
US20120128587A1 (en) * 2009-07-31 2012-05-24 Endocyte, Inc. Folate-targeted diagnostics and treatment
CA2793657A1 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
WO2012149416A2 (en) * 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
WO2013082591A1 (en) * 2011-12-02 2013-06-06 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CN106456628A (zh) * 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
EP3215844B1 (en) * 2014-08-19 2021-04-28 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062697A2 (en) * 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
WO2016085967A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERRIT JANSEN ET AL: PTERIDINES., vol. 26, no. 2, 1 January 2015 (2015-01-01), AT, pages 41 - 53, XP055447538, ISSN: 0933-4807, DOI: 10.1515/pterid-2015-0005 *
JIAYIN SHEN: "FOLATE RECEPTOR BETA: A NEW SURFACE MOLECULE FOR SELECTIVE TARGETING OF ACTIVATED MACROPHAGES IN INFLAMMATORY DISEASES AND CANCER Doctor of Philosophy", 1 May 2013 *
Matson, Vyara, "Migration of Myeloid-derived Suppressor Cells to Tumor and Tumor-Draining Lymph Node in a murine model of breast cancer", Thesis, Aug 2015, University of Wisconsin Milwaukee UWM Digital Commons. *

Also Published As

Publication number Publication date
EP3463367A1 (en) 2019-04-10
CN109475558A (zh) 2019-03-15
KR102489277B1 (ko) 2023-01-16
BR112018074119A2 (pt) 2019-03-06
IL263059B1 (en) 2024-10-01
RU2018145750A (ru) 2020-06-25
JP7278777B2 (ja) 2023-05-22
KR20190021261A (ko) 2019-03-05
WO2017205661A1 (en) 2017-11-30
AU2017271550A1 (en) 2018-12-06
NZ748427A (en) 2025-05-30
EP3463367A4 (en) 2020-01-29
IL263059A (en) 2018-12-31
IL263059B2 (en) 2025-02-01
US20210170035A1 (en) 2021-06-10
RU2018145750A3 (cg-RX-API-DMAC7.html) 2020-07-30
US20190216935A1 (en) 2019-07-18
CN114903890A (zh) 2022-08-16
CA3025309A1 (en) 2017-11-30
JP2019519524A (ja) 2019-07-11

Similar Documents

Publication Publication Date Title
US20210170035A1 (en) Method of treating cancer by targeting myeloid-derived suppressor cells
AU2004210136B8 (en) Vitamin receptor binding drug delivery conjugates
AU2019209432B2 (en) Methods of use for CAR T cells
JP5675619B2 (ja) 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
JP5690589B2 (ja) 親水性スペーサーリンカーを含有する結合体
US20230241227A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
JP5475992B2 (ja) 多剤リガンド結合体
US9555139B2 (en) Binding ligand linked drug delivery conjugates of tubulysins
CA3019835A1 (en) Methods and compositions for car t cell therapy
US20220175875A1 (en) Methods of treating cancer by targeting tumor-associated macrophages
US11981672B2 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
US20230285556A1 (en) Methods and compositions for treating cancer
CA3025309C (en) Method of treating cancer by targeting myeloid-derived suppressor cells
CA3203439A1 (en) Methods for enhancement of engineered cell therapies in cancer treatment
RU2776899C2 (ru) Способ лечения рака нацеливанием на супрессорные клетки миелоидного происхождения
BR112018074119B1 (pt) Uso de compostos compreendendo um ligante de ligação de receptor folato ligado a um fármaco via um ligante, e composição farmacêutica
US20240376118A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
JP2026509589A (ja) がん処置においてチェックポイント阻害剤治療を増強させるための組合せ物および方法
WO2024102810A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP4395782A1 (en) Conjugates, compositions, and methods for rejuvenation of car t-cells

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 25 MAY 2021 TO 25 JAN 2022 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 25 JAN 2022

FGA Letters patent sealed or granted (standard patent)